Why Women’s Health Remains Underinvested: The Gap Between Market Size and Capital Deployed
1. The Paradox: A Massive Market Chronically Underserved by Capital
Women constitute slightly more than 50% of the global population, make approximately 80% of household healthcare decisions, consume an estimated 66% of healthcare services in the US, and live longer than men — meaning their lifetime healthcare spend is higher. By any standard commercial logic, women’s health should be one of the most heavily invested sectors in healthcare.
It is not.
FemTech represents approximately 3–4% of total digital health investment globally — a share that is dramatically disproportionate to the market opportunity. The gap is not explained by lack of clinical need (unmet need in women’s health is extensively documented across menopause, endometriosis, autoimmune conditions, cardiovascular disease presentation, and mental health). Nor is it explained by lack of market size ($63B in 2025, growing at 16%+ CAGR). The gap is explained by structural dynamics in how capital is deployed — dynamics that are now beginning to shift.
2. The Evidence Base for Underinvestment
Clinical Research Gap
Women were systematically excluded from clinical trials for decades — the NIH Revitalization Act of 1993 mandated their inclusion, but implementation was slow and inconsistent. The consequences persist in 2026: most drug and device approvals are based predominantly on male study populations, despite documented sex differences in disease presentation, treatment response, and outcomes.
For AI medical device companies, this creates a specific and underappreciated risk: models trained predominantly on male patient data perform less accurately on female patients — a form of algorithmic sex bias that has been documented in cardiac AI, dermatology AI, and pain assessment algorithms. Investors increasingly recognize this as regulatory and commercial risk.
Conditions That Disproportionately Affect Women: Chronically Underfunded
Several conditions that predominantly or exclusively affect women receive research and development investment dramatically below their disease burden:
Endometriosis: affects an estimated 190 million women globally (approximately 10% of reproductive-age women), causes significant disability and quality-of-life impairment, and receives an estimated $9 per affected person per year in NIH research funding — compared to $250+ per person for HIV, which affects far fewer Americans. Average time to diagnosis remains 7–10 years.
Menopause: affects 1.2 billion women globally, with documented impact on cardiovascular health, bone density, cognitive function, and mental health. Despite this scale, menopause care was largely absent from medical school curricula until recently — 80% of OB-GYNs lack formal menopause training. Hormone therapy prescribing has been shaped more by the controversy around the 2002 Women’s Health Initiative than by the current evidence base.
Autoimmune Conditions: approximately 80% of autoimmune disease cases occur in women, yet many autoimmune conditions receive investment and research attention inconsistent with this demographic concentration.
Female-pattern cardiovascular disease: heart disease is the leading cause of death in women, but women present with different symptoms than men, are less likely to be enrolled in cardiovascular trials, and are diagnosed and treated less aggressively. AI cardiac diagnostics trained predominantly on male datasets have documented accuracy gaps in female patient populations.
3. Why Capital Has Been Slow to Follow
The “Small Market” Misperception
For decades, the implicit frame in healthcare investment was that conditions affecting only women were, by definition, niche markets. This logic confuses the market for a specific indication with the demographic reality of 4 billion potential patients. The menopause market, serving women aged 45–65, covers a demographic that is one of the highest-spending healthcare consumer segments in the developed world.
The reframing that is finally occurring in investment circles: women’s health conditions are not niche. They are large markets that have been neglected and are now experiencing the economic consequences of two generations of underinvestment in clinical infrastructure, physician training, and product development.
VC Demographic Gap
The investment community managing capital into women’s health has historically been demographically distant from the patient population. A frequently cited analysis found that only 10–15% of healthcare VC partners in the US are women. This demographic gap correlates with systematic underweighting of women’s health opportunities in investment portfolio construction.
This is changing: several women-founded and women-focused funds have launched in 2022–2025, explicitly targeting the FemTech underinvestment opportunity. Portfolios from these funds are demonstrating strong performance — driven by the structural advantage of investing in an underpriced category.
The Consumer-vs-Clinical Category Confusion
Early FemTech was largely consumer wellness — apps, tracking tools, and devices that fell below the regulatory threshold for medical devices. Investor experience with first-generation FemTech (high burn, high churn, limited monetization) created a lasting negative prior that has been slow to update as the category has evolved into clinically validated, B2B-distributed, reimbursement-supported infrastructure.
The updating is now happening. Maven Clinic’s $1.7B valuation, the rapid growth of menopause care platforms, and the emergence of women’s health as an explicitly prioritized category by CMS and major payers are creating a new reference set that investors are using to recalibrate.
4. Where the Capital Gap Is Largest — and Why That Matters
Menopause: $600B Market, Minimal Clinical Infrastructure
The menopause care market is the clearest example of capital-market gap in women’s health. Despite a market projected to reach $600 billion by 2030, the clinical infrastructure to support evidence-based menopause management — trained physicians, validated diagnostics, digital care management platforms — barely exists.
Companies entering this space in 2025–2026 face low competition from incumbents (there are no dominant menopause care platforms), strong employer and payer interest (menopause symptoms are documented to drive significant productivity loss and healthcare utilization), and a scientifically sophisticated patient population who have already self-educated on the evidence base.
Non-Hormonal Contraception: Regulatory Pathway Unclear, Market Large
An estimated 60% of women of reproductive age who use contraception report concerns about hormonal side effects. Non-hormonal contraception options are extremely limited — condoms and copper IUDs have significant limitation profiles. The FDA approved Phexxi (lactic acid/citric acid/potassium bitartrate gel) in 2020, but pipeline development of novel non-hormonal mechanisms remains thin relative to demand.
Companies developing non-hormonal contraception face longer development timelines than digital health but address a market with clear demand signal and regulatory pathway precedents.
Sexual Health: The Last Taboo in Institutional Investment
Female sexual dysfunction — hypoactive sexual desire disorder (HSDD), sexual pain disorders, arousal dysfunction — affects an estimated 43% of women but receives disproportionately limited research investment compared to male sexual health. Addyi (flibanserin, FDA approved 2015) and Vyleesi (bremelanotide, FDA approved 2019) demonstrated regulatory pathway viability, but commercial execution has been limited.
Digital health companies addressing female sexual health are navigating both commercial and cultural barriers — but those that establish clinical evidence and navigate regulatory pathways successfully are entering a large and chronically underserved market.
5. The Investor Opportunity: Structuring for the Gap
For investors seeking to capture the underinvestment alpha in women’s health, several strategies offer differentiated access:
Lead Rounds in Menopause and Perimenopause Care
Companies building clinical care infrastructure for menopause — telehealth platforms, hormone therapy management, bone health, cardiovascular risk — are the highest-conviction opportunity in the current market. The category has employer-payer interest, documented clinical need, and minimal incumbent competition.
Support Endometriosis and Reproductive Pain Research Platforms
The endometriosis diagnostic gap (7–10 year average diagnosis delay) creates opportunity for AI-enhanced diagnostic tools, non-invasive biomarker discovery, and digital care management platforms. Several endometriosis startups are in Series A–B fundraising with compelling evidence of diagnostic acceleration.
Cardiovascular AI with Sex-Disaggregated Validation
AI cardiac diagnostic companies that explicitly train and validate on sex-disaggregated datasets are addressing both the clinical accuracy gap and the regulatory scrutiny increasingly applied to algorithmic fairness in medical AI. This is a differentiating feature in enterprise procurement and regulatory review.
FemTech-Focused Funds as Portfolio Exposure
For family offices and institutional investors preferring diversified exposure, several dedicated FemTech investment vehicles have launched in 2022–2025 with explicitly documented investment theses targeting the underinvestment gap. These funds offer diversified portfolio construction with managers who have deep domain expertise in both clinical and commercial aspects of women’s health.
6. What Needs to Change — and What Is Changing
CMS and Payer Movement
CMS has expanded coverage for menopause counseling under Medicare in 2025, and several large commercial payers have added menopause care management as an explicit benefits category. This reimbursement movement follows a familiar pattern: payer coverage creates commercial viability, which attracts product development investment, which builds the clinical evidence base, which expands coverage further.
NIH Funding Allocation
The NIH Office of Research on Women’s Health has been systematically expanding its budget and funding priorities, with particular emphasis on menopause, endometriosis, and autoimmune conditions. NIH funding signals are leading indicators of subsequent commercial investment — biotechs and digital health companies typically follow NIH-funded research into clinical development.
Employer Benefits as Market Development
Employer-sponsored women’s health benefits — now offered by a significant and growing fraction of Fortune 500 companies — are creating a new revenue channel that did not exist at scale five years ago. As more employers document the ROI of women’s health benefits (in reduced absenteeism, improved retention, lower healthcare claims), the employer channel will expand and attract more product development investment.
7. Conclusion
Women’s health underinvestment is not a mystery — it is the predictable outcome of decades of demographic bias in investment decision-making, clinical research design, and regulatory priority-setting. What is different in 2026 is that the forces correcting this imbalance are structural and durable: payer coverage expansion, employer channel development, regulatory emphasis on sex-disaggregated evidence, and a growing cohort of investors with both the domain expertise and the mandate to deploy capital into women’s health.
For investors: the risk-adjusted return opportunity in women’s health is arguably the highest in digital health for a simple reason — the market is large, the need is documented, and the capital is late. Early movers in menopause care, endometriosis diagnostics, and cardiovascular AI with sex-disaggregated validation are building positions in markets that will attract substantially more capital over the next 5–7 years.
For founders: building in women’s health in 2026 requires clinical seriousness — evidence-based products, validated outcomes, regulatory clarity, and B2B distribution architecture. Consumer wellness without clinical validation will not attract institutional capital. Clinical depth with employer-payer distribution will.
Sources: Astute Analytica FemTech Market 2035 · Longevity Investors Menopause Analysis · Fortune Business Insights FemTech · Grand View Research FemTech · Precedence Research FemTech